Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives

Stefania Gori, Massimo Barberis, Maria Angela Bella, Fiamma Buttitta, Ettore Capoluongo, Paola Carrera, Nicoletta Colombo, Laura Cortesi, Maurizio Genuardi, Massimo Gion, Valentina Guarneri, Lorena Incorvaia, Nicla La Verde, Domenica Lorusso, Antonio Marchetti, Paolo Marchetti, Nicola Normanno, Barbara Pasini, Matilde Pensabene, Sandro Pignata & 9 others Paolo Radice, Enrico Ricevuto, Anna Sapino, Pierosandro Tagliaferri, Pierfrancesco Tassone, Chiara Trevisiol, Mauro Truini, Liliana Varesco, Antonio Russo

Research output: Contribution to journalReview article

Abstract

The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing. The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance clinics and specific risk-reducing measures (primary and/or secondary prevention programs).

Original languageEnglish
Pages (from-to)67-72
Number of pages6
JournalCritical Reviews in Oncology/Hematology
Volume140
DOIs
Publication statusPublished - Aug 1 2019

Fingerprint

Ovarian Neoplasms
BRCA1 Gene
Neoplasms
Primary Prevention
Secondary Prevention
Therapeutics
Guidelines

Keywords

  • BRCA1
  • BRCA2
  • Genetic testing
  • Germline mutations
  • Ovarian cancer
  • PARP inhibitors
  • Somatic mutations

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cite this

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. / Gori, Stefania; Barberis, Massimo; Bella, Maria Angela; Buttitta, Fiamma; Capoluongo, Ettore; Carrera, Paola; Colombo, Nicoletta; Cortesi, Laura; Genuardi, Maurizio; Gion, Massimo; Guarneri, Valentina; Incorvaia, Lorena; La Verde, Nicla; Lorusso, Domenica; Marchetti, Antonio; Marchetti, Paolo; Normanno, Nicola; Pasini, Barbara; Pensabene, Matilde; Pignata, Sandro; Radice, Paolo; Ricevuto, Enrico; Sapino, Anna; Tagliaferri, Pierosandro; Tassone, Pierfrancesco; Trevisiol, Chiara; Truini, Mauro; Varesco, Liliana; Russo, Antonio.

In: Critical Reviews in Oncology/Hematology, Vol. 140, 01.08.2019, p. 67-72.

Research output: Contribution to journalReview article

Gori, Stefania ; Barberis, Massimo ; Bella, Maria Angela ; Buttitta, Fiamma ; Capoluongo, Ettore ; Carrera, Paola ; Colombo, Nicoletta ; Cortesi, Laura ; Genuardi, Maurizio ; Gion, Massimo ; Guarneri, Valentina ; Incorvaia, Lorena ; La Verde, Nicla ; Lorusso, Domenica ; Marchetti, Antonio ; Marchetti, Paolo ; Normanno, Nicola ; Pasini, Barbara ; Pensabene, Matilde ; Pignata, Sandro ; Radice, Paolo ; Ricevuto, Enrico ; Sapino, Anna ; Tagliaferri, Pierosandro ; Tassone, Pierfrancesco ; Trevisiol, Chiara ; Truini, Mauro ; Varesco, Liliana ; Russo, Antonio. / Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. In: Critical Reviews in Oncology/Hematology. 2019 ; Vol. 140. pp. 67-72.
@article{beebfe0f6d52403ca1681165bcb159b5,
title = "Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives",
abstract = "The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing. The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance clinics and specific risk-reducing measures (primary and/or secondary prevention programs).",
keywords = "BRCA1, BRCA2, Genetic testing, Germline mutations, Ovarian cancer, PARP inhibitors, Somatic mutations",
author = "Stefania Gori and Massimo Barberis and Bella, {Maria Angela} and Fiamma Buttitta and Ettore Capoluongo and Paola Carrera and Nicoletta Colombo and Laura Cortesi and Maurizio Genuardi and Massimo Gion and Valentina Guarneri and Lorena Incorvaia and {La Verde}, Nicla and Domenica Lorusso and Antonio Marchetti and Paolo Marchetti and Nicola Normanno and Barbara Pasini and Matilde Pensabene and Sandro Pignata and Paolo Radice and Enrico Ricevuto and Anna Sapino and Pierosandro Tagliaferri and Pierfrancesco Tassone and Chiara Trevisiol and Mauro Truini and Liliana Varesco and Antonio Russo",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.critrevonc.2019.05.012",
language = "English",
volume = "140",
pages = "67--72",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives

AU - Gori, Stefania

AU - Barberis, Massimo

AU - Bella, Maria Angela

AU - Buttitta, Fiamma

AU - Capoluongo, Ettore

AU - Carrera, Paola

AU - Colombo, Nicoletta

AU - Cortesi, Laura

AU - Genuardi, Maurizio

AU - Gion, Massimo

AU - Guarneri, Valentina

AU - Incorvaia, Lorena

AU - La Verde, Nicla

AU - Lorusso, Domenica

AU - Marchetti, Antonio

AU - Marchetti, Paolo

AU - Normanno, Nicola

AU - Pasini, Barbara

AU - Pensabene, Matilde

AU - Pignata, Sandro

AU - Radice, Paolo

AU - Ricevuto, Enrico

AU - Sapino, Anna

AU - Tagliaferri, Pierosandro

AU - Tassone, Pierfrancesco

AU - Trevisiol, Chiara

AU - Truini, Mauro

AU - Varesco, Liliana

AU - Russo, Antonio

PY - 2019/8/1

Y1 - 2019/8/1

N2 - The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing. The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance clinics and specific risk-reducing measures (primary and/or secondary prevention programs).

AB - The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing. The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance clinics and specific risk-reducing measures (primary and/or secondary prevention programs).

KW - BRCA1

KW - BRCA2

KW - Genetic testing

KW - Germline mutations

KW - Ovarian cancer

KW - PARP inhibitors

KW - Somatic mutations

UR - http://www.scopus.com/inward/record.url?scp=85066629041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066629041&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2019.05.012

DO - 10.1016/j.critrevonc.2019.05.012

M3 - Review article

VL - 140

SP - 67

EP - 72

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -